STOCK TITAN

MediWound Ltd - MDWD STOCK NEWS

Welcome to our dedicated news page for MediWound (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on MediWound.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MediWound's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MediWound's position in the market.

Rhea-AI Summary
MediWound Ltd. announces EscharEx superiority over SANTYL in wound debridement and wound closure for chronic venous leg ulcers. Phase II study shows EscharEx outperforming SANTYL in complete debridement, granulation tissue promotion, and wound closure time. Promising results position EscharEx as a potential market leader in enzymatic agents for chronic wound treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
clinical trial
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) will participate in the Oppenheimer 34th Annual Life Sciences Conference on February 13-14, 2024, and the TD Cowen 44th Annual Health Care Conference on March 4-6, 2024. The management team will host one-on-one meetings during both conferences, and interested investors can schedule meetings through their Oppenheimer and/or TD Cowen representative. Links to access the fireside chat and company presentation will be posted on MediWound’s website. The company is focused on next-generation enzymatic therapeutics for tissue repair.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.69%
Tags
conferences
-
Rhea-AI Summary
MediWound Ltd. (MDWD) announced that the U.S. FDA has accepted a supplement to the NexoBrid biologics license application for the removal of eschar in pediatric patients with deep partial- and/or full-thickness thermal burns. NexoBrid is already approved for use for burn patients across all age groups in Europe and Japan. The sBLA seeks to expand the label for NexoBrid to include both adult and pediatric burn patients of all ages, based on the results of a global Phase 3 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
none
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) awarded an additional $6.7 million to advance NexoBrid as a non-surgical field care solution, increasing the R&D project budget to $14.4 million. The U.S. Department of Defense, through the Medical Technology Enterprise Consortium, granted the funding to develop NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army. The project aims to advance the development and production of a new, temperature-stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings. Vericel Corporation holds an exclusive license encompassing the commercial and development rights to NexoBrid in North America. The additional funding will enhance CMC activities, expedite preclinical development, and facilitate the establishment of a GMP compliant aseptic production line for the temperature-stable formulation of NexoBrid. The MTEC Research Project Award was granted by the DoD’s U.S. Army Medical Research and Development Command and funded by the Defense Health Agency through MTEC, a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) announces positive results from a Phase II study of EscharEx, a novel bromelain-based enzymatic debridement agent, in patients with venous leg ulcers and diabetic foot ulcers. The study shows that EscharEx effectively debrides wounds, reduces biofilm and bacterial load, achieving complete debridement in 70% of patients within a median time of 5.5 days. The treatment also led to an average reduction of 35% in wound size and was well tolerated. The company plans to initiate a Phase III pivotal study in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
Rhea-AI Summary
MediWound Ltd. (MDWD) announces commercial launch of NexoBrid in the U.S. and Japan, with a focus on meeting increased global demand. Cash of $46 million ensures operational cash runway through profitability. Third quarter 2023 revenues at $4.8 million, a decrease from $5.8 million in the same period last year. Gross profit at $0.9 million, operating loss at $3.0 million, and net loss at $2.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
earnings
Rhea-AI Summary
MediWound Ltd. (MDWD) appoints Dr. Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, effective December 1, 2023. Dr. Hess brings over two decades of expertise in drug development and commercial operations in healthcare, with a track record of leading international operations and commercial activities in the global biopharma industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
management
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) to release Q3 2023 financial results on November 21, 2023. The company will host a conference call and webcast to discuss the results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences earnings
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) announced a positive opinion from the European Medicines Agency recommending a label expansion for NexoBrid to include all age groups for removal of eschar in patients with deep partial- and full-thickness thermal burns. This expansion is based on the results of a global Phase 3 trial and additional pediatric data, confirming NexoBrid's safety and efficacy. The expansion is expected to redefine the standard of care for severe burns and significantly increase the company's addressable market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) and PolyMedics Innovations (PMI) have announced a collaboration to promote NexoBrid® in Germany, Austria, Belgium, the Netherlands, and Luxemburg. NexoBrid, a non-surgical solution for eschar removal in burns, complements PMI's existing product line, allowing for a comprehensive solution for burn patients. The agreement aims to drive increased utilization of NexoBrid in the specified regions, leveraging PMI's customer access and commercial resources.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
MediWound Ltd

Nasdaq:MDWD

MDWD Rankings

MDWD Stock Data

129.07M
4.99M
26.46%
34.58%
0.62%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Israel
42 Hayarkon Street

About MDWD

mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and